Montelukast

Drugs

Volumn 56, Issue 2, 1998, Pages 251-256

  Markham, A ^a   Faulds, D ^a   Pauwels, R A ^a   Burgess, C ^a   Crane, J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE D4 RECEPTOR; MONTELUKAST;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; COUGHING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; EXERCISE; FLUSHING; HEADACHE; HUMAN; INFLUENZA; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION;

ACARI;

EID: 0031816891     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856020-00010     Document Type: Article

References (26)

1. 1. TR Jones E Champion L Charette 1994 Pharmacology of MK-0476, a potent and selective leukotriene D-4-receptor antagonist [abstract] Am J Respir Crit Care Med 149 463 Jones TR, Champion E, Charette L, et al. Pharmacology of MK-0476, a potent and selective leukotriene D-4-receptor antagonist [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (2 Pt 1): 463
2. 2. DC Grootendorst Z Diamant M Veselic 1997 Effect of oral montelukast, a cysLT 1-receptor antagonist, on eosinophil counts and ECP in induced sputum before and after allergen challenge in asthmatics [abstract] Am J Respir Crit Care Med 155 4 A976 Grootendorst DC, Diamant Z, Veselic M, et al. Effect of oral montelukast, a cysLT 1-receptor antagonist, on eosinophil counts and ECP in induced sputum before and after allergen challenge in asthmatics [abstract]. Am J Respir Crit Care Med 1997; 155(4): A976
3. 3. JA Leff E Pizzichini A Efthimiadis 1997 Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial [abstract] Am J Respir Crit Care Med 155 4 A977 Leff JA, Pizzichini E, Efthimiadis A, et al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial [abstract]. Am J Respir Crit Care Med 1997; 155(4): A977
4. 4. I De-Lepeleire TF Reiss F Rochette 1997 Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma Clin Pharmacol Ther 61 83 92 9024176 10.1016/S0009-9236(97)90184-3 1:CAS:528:DyaK2sXhvVaiur8%3D De-Lepeleire I, Reiss TF, Rochette F, et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997 Jan; 61: 83–92
5. 5. Z Diamant MC Timmers H Veen van der 1996 Effect of oral montelukast (MK-0476), a potent leukotriene receptor antagonist, on allergen-induced airway responses in asthmatic subjects [abstract] Am J Respir Crit Care Med 153 A346 Diamant Z, Timmers MC, van der Veen H, et al. Effect of oral montelukast (MK-0476), a potent leukotriene receptor antagonist, on allergen-induced airway responses in asthmatic subjects [abstract]. Am J Respir Crit Care Med 1996; 153: A346
6. 6. TF Reiss E Bronsky L Hendeles 1995 MK-0476, a potent leukotriene (LT)D 4 receptor antagonist inhibits exercise induced bronchoconstriction in asthmatics at the end of a once daily dosing interval [abstract] Am J Respir Crit Care Med 151 4 A377 Reiss TF, Bronsky E, Hendeles L, et al. MK-0476, a potent leukotriene (LT)D 4 receptor antagonist inhibits exercise induced bronchoconstriction in asthmatics at the end of a once daily dosing interval [abstract]. Am J Respir Crit Care Med 1995; 151(4): A377
7. 7. TF Reiss E Bronsky J Kemp 1995 MK-0476, a potent and specific leukotriene D4 receptor antagonist exhibits a dose response in the inhibition of exercise induced bronchoconstriction at the end of a once daily dosing interval [abstract] J Invest Med 43 2 275 Reiss TF, Bronsky E, Kemp J. MK-0476, a potent and specific leukotriene D4 receptor antagonist exhibits a dose response in the inhibition of exercise induced bronchoconstriction at the end of a once daily dosing interval [abstract]. J Invest Med 1995 Apr; 43 Suppl. 2: 275A
8. 8. EA Bronsky JP Kemp J Zhang 1997 Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval Clin Pharmacol Ther 62 556 61 9390112 10.1016/S0009-9236(97)90051-5 1:CAS:528:DyaK2sXnvVGrtbw%3D Bronsky EA, Kemp JP, Zhang J, et al. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997 Nov; 62: 556–61
9. 9. JA Leff EA Bronsky J Kemp 1997 Montelukast (MK-0476) inhibits exercise-induced bronchoconstriction (EIB) over 12-weeks without causing tolerance [abstract] Am J Respir Crit Care Med 155 4 A977 Leff JA, Bronsky EA, Kemp J, et al. Montelukast (MK-0476) inhibits exercise-induced bronchoconstriction (EIB) over 12-weeks without causing tolerance [abstract]. Am J Respir Crit Care Med 1997; 155(4): A977
10. 10. JP Kemp RJ Dockhorn GG Shapiro 1997 Montelukast, a leukotriene receptor antagonist, inhibits exercise-induced bronchoconstriction in 6-to-14-year old children [abstract] J Allergy Clin Immunol 99 321 Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast, a leukotriene receptor antagonist, inhibits exercise-induced bronchoconstriction in 6-to-14-year old children [abstract]. J Allergy Clin Immunol 1997 Jan; 99 (Pt 2): 321
11. 11. H Cheng JA Leff R Amin 1996 Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females Pharm Res 13 445 8 8692739 10.1023/A:1016056912698 1:CAS:528:DyaK28XhvVOiu7g%3D Cheng H, Leff JA, Amin R, et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996 Mar; 13: 445–8
12. 12. Merck & Co., Inc. Montelukast prescribing information. White-house Station, New Jersey, USA, 1997
13. 13. JJ Zhao JD Rogers SD Holland 1997 Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers Biopharm Drug Dispos 18 769 77 9429741 10.1002/(SICI)1099-081X(199712)18:9<769::AID-BDD60>3.0.CO;2-K 1:CAS:528:DyaK1cXms12q Zhao JJ, Rogers JD, Holland SD, et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 1997 Dec; 18: 769–77
14. 14. SK Balani X Xu V Pratha 1997 Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene, receptor antagonist, in human plasma and bile Drug Metab Dispos 25 1282 7 9351905 1:CAS:528:DyaK2sXntlOrsro%3D Balani SK, Xu X, Pratha V, et al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene, receptor antagonist, in human plasma and bile. Drug Metab Dispos 1997 Nov; 25: 1282–7
15. 15. TF Reiss CA Sorkness W Stricker 1997 Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids Thorax 52 45 8 9039239 10.1136/thx.52.1.45 1:STN:280:DyaK2s7ptFarsw%3D%3D Reiss TF, Sorkness CA, Stricker W, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997 Jan; 52: 45–8
16. 16. TF Reiss LC Altman P Chervinsky 1996 Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma J Allergy Clin Immunol 98 528 34 8828530 10.1016/S0091-6749(96)70086-6 1:CAS:528:DyaK28XmsFSlurg%3D Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996 Sep; 98: 528–34
17. 17. CA Sorkness TF Reiss J Zhang 1994 Bronchodilation with a selective and potent leukotriene D-4 antagonist (MK-0476) in patients with asthma [abstract] Am J Respir Crit Care Med 2 216 Sorkness CA, Reiss TF, Zhang J, et al. Bronchodilation with a selective and potent leukotriene D-4 antagonist (MK-0476) in patients with asthma [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt 2: 216
18. 18. TF Reiss LC Altaian ZM Munk 1995 MK-0476 an LTD 4 receptor antagonist improves the signs and symptoms of asthma with a dose as low as 10 mg once daily [abstract] Am J Respir Crit Care Med 151 4 A378 Reiss TF, Altaian LC, Munk ZM, et al. MK-0476 an LTD 4 receptor antagonist improves the signs and symptoms of asthma with a dose as low as 10 mg once daily [abstract]. Am J Respir Crit Care Med 1995; 151(4): A378
19. 19. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998 (11): 1232–1239
20. 20. TF Reiss P Chervinsky T Edwards 1996 Montelukast (MK-0476), a CysLT1 receptor antagonist, improves the signs and symptoms of asthma over a 3 month treatment period [abstract] Eur Respir J 9 23 273 Reiss TF, Chervinsky P, Edwards T, et al. Montelukast (MK-0476), a CysLT1 receptor antagonist, improves the signs and symptoms of asthma over a 3 month treatment period [abstract]. Eur Respir J 1996 Sep; 9 Suppl. 23: 273
21. 21. TF Reiss R White G Noonan 1997 Montelukast (MK-0476), A CysLT 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment [abstract] Eur Respir J 10 437s 10.1183/09031936.97.10020437 Reiss TF, White R, Noonan G, et al. Montelukast (MK-0476), A CysLT 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment [abstract]. Eur Respir J 1997 Sep; 10 (25 Suppl.): 437s
22. 22. JA Leff E Israel MJ Noonan 1997 Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability [abstract] Am J Respir Crit Care Med 155 4 A976 Leff JA, Israel E, Noonan MJ, et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability [abstract]. Am J Respir Crit Care Med 1997; 155(4): A976
23. 23. P Kuna K Malmstrom SE Dahlen 1997 Montelukast(MK-0476) a CysLTi receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients [abstract] Am J Respir Crit Care Med 155 A975 Kuna P, Malmstrom K, Dahlen SE, et al. Montelukast(MK-0476) a CysLTi receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients [abstract]. Am J Respir Crit Care Med 1997; 155 (4 Suppl.): A975
24. 24. B Knorr J Matz JA Bernstein 1998 Montelukast for chronic asthma in 6-to 14-year-old children JAMA 279 15 1181 6 9555757 10.1001/jama.279.15.1181 1:CAS:528:DyaK1cXislCjurY%3D Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6-to 14-year-old children. JAMA 1998 Apr 15; 279(15): 1181–6
25. 25. BA Knorr J Matz RJ Sveum 1997 Montelukast (MK-0476) improves asthma over 6 months of treatment in 6-to 14-year old patients [abstract] Eur Respir J 10 25 219s Knorr BA, Matz J, Sveum RJ, et al. Montelukast (MK-0476) improves asthma over 6 months of treatment in 6-to 14-year old patients [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 219s
26. 26. DF Schoors M Smet De T Reiss 1995 Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers Br J Clin Pharmacol 40 277 80 8527292 10.1111/j.1365-2125.1995.tb05785.x 1:CAS:528:DyaK2MXosl2ltro%3D Schoors DF, De Smet M, Reiss T, et al. Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. Br J Clin Pharmacol 1995 Sep; 40: 277–80